[go: up one dir, main page]

PL3341368T3 - Nowe analogi nukleozydowe podstawione 6-6 bicykicznym pierścieniem aromatycznym do zostosowania jako inhibitory prmt5 - Google Patents

Nowe analogi nukleozydowe podstawione 6-6 bicykicznym pierścieniem aromatycznym do zostosowania jako inhibitory prmt5

Info

Publication number
PL3341368T3
PL3341368T3 PL16757233T PL16757233T PL3341368T3 PL 3341368 T3 PL3341368 T3 PL 3341368T3 PL 16757233 T PL16757233 T PL 16757233T PL 16757233 T PL16757233 T PL 16757233T PL 3341368 T3 PL3341368 T3 PL 3341368T3
Authority
PL
Poland
Prior art keywords
novel
aromatic ring
ring substituted
bicyclic aromatic
nucleoside analogues
Prior art date
Application number
PL16757233T
Other languages
English (en)
Polish (pl)
Inventor
Tongfei Wu
Dirk Brehmer
Lijs Beke
An Boeckx
Gaston Stanislas Marcella Diels
Ronaldus Arnodus Hendrika Joseph Gilissen
Edward Charles LAWSON
Vineet PANDE
Marcus Cornelis Bernardus Catharina Parade
Wim Bert Griet Schepens
Johannes Wilhelmus John F Thuring
Marcel Viellevoye
Weimei SUN
Lieven Meerpoel
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL3341368T3 publication Critical patent/PL3341368T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL16757233T 2015-08-26 2016-08-25 Nowe analogi nukleozydowe podstawione 6-6 bicykicznym pierścieniem aromatycznym do zostosowania jako inhibitory prmt5 PL3341368T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562209941P 2015-08-26 2015-08-26
EP15184011 2015-09-07
US201662306233P 2016-03-10 2016-03-10
EP16757233.8A EP3341368B1 (fr) 2015-08-26 2016-08-25 Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
PCT/EP2016/070097 WO2017032840A1 (fr) 2015-08-26 2016-08-25 Nouveaux analogues nucléosidiques substitués par un cycle aromatique bicyclique 6-6 utiles comme inhibiteurs de prmt5

Publications (1)

Publication Number Publication Date
PL3341368T3 true PL3341368T3 (pl) 2022-02-14

Family

ID=54065259

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16757233T PL3341368T3 (pl) 2015-08-26 2016-08-25 Nowe analogi nukleozydowe podstawione 6-6 bicykicznym pierścieniem aromatycznym do zostosowania jako inhibitory prmt5

Country Status (35)

Country Link
US (4) US10653711B2 (fr)
EP (3) EP3341368B1 (fr)
JP (3) JP6917978B2 (fr)
KR (1) KR102716092B1 (fr)
CN (2) CN114057815B (fr)
AR (1) AR105820A1 (fr)
AU (4) AU2016311295B2 (fr)
BR (2) BR122023020317A2 (fr)
CA (1) CA2992688A1 (fr)
CL (1) CL2018000510A1 (fr)
CO (1) CO2018002063A2 (fr)
CY (1) CY1125359T1 (fr)
DK (1) DK3341368T3 (fr)
EA (1) EA201890573A1 (fr)
ES (1) ES2901972T3 (fr)
HR (1) HRP20211997T1 (fr)
HU (1) HUE057312T2 (fr)
IL (3) IL311843A (fr)
LT (1) LT3341368T (fr)
MA (1) MA42678B1 (fr)
MD (1) MD3341368T2 (fr)
MX (2) MX392554B (fr)
MY (1) MY198472A (fr)
NZ (2) NZ779003A (fr)
PE (2) PE20221629A1 (fr)
PH (2) PH12018500425B1 (fr)
PL (1) PL3341368T3 (fr)
PT (1) PT3341368T (fr)
RS (1) RS62698B1 (fr)
SG (1) SG10202003775VA (fr)
SI (1) SI3341368T1 (fr)
SM (1) SMT202100725T1 (fr)
TN (1) TN2018000043A1 (fr)
TW (3) TWI870767B (fr)
WO (1) WO2017032840A1 (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI870767B (zh) * 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
UA123637C2 (uk) * 2016-03-10 2021-05-05 Янссен Фармацевтика Нв Заміщені аналоги нуклеозидів для застосування як інгібіторів prmt5
CA2969295A1 (fr) * 2016-06-06 2017-12-06 Pfizer Inc. Derives de carbonucleosides substitues et leur utilisation comme inhibiteur de prmt5
WO2018050684A1 (fr) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
SI3512857T1 (sl) 2016-09-14 2021-07-30 Janssen Pharmaceutica Nv Spiro biciklični zaviralci interakcije menin-MLL
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
WO2018065365A1 (fr) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
MA46341A (fr) 2016-10-03 2019-08-07 Janssen Pharmaceutica Nv Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
JP7142010B2 (ja) 2016-12-15 2022-09-26 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のアゼパン阻害剤
GB201700526D0 (en) * 2017-01-12 2017-03-01 Univ Of Hull Therapeutic use
AU2018225312B2 (en) 2017-02-27 2024-02-08 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
EP3939986A1 (fr) 2017-08-09 2022-01-19 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
CA3079545A1 (fr) * 2017-10-26 2019-05-02 Prelude Therapeutics, Incorporated Inhibiteurs selectifs de la proteine arginine methyltransferase 5 (prmt5)
AU2018381004B2 (en) * 2017-12-05 2021-04-29 Angex Pharmaceutical, Inc. Heterocyclic compounds as PRMT5 inhibitors
MA51004A (fr) 2017-12-08 2020-10-14 Janssen Pharmaceutica Nv Nouveaux analogues spirobicycliques
US11459330B2 (en) * 2017-12-13 2022-10-04 Lupin Limited Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
FI3765461T3 (fi) * 2018-03-14 2023-11-13 Prelude Therapeutics Inc Proteiiniarginiinimetyylitransferaasi-5:n (prmt5) selektiivisiä estäjiä
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
MX2021001486A (es) * 2018-08-07 2021-07-15 Merck Sharp & Dohme Llc Inhibidores prmt5.
US20210309687A1 (en) * 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668B1 (fr) * 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3897667A4 (fr) * 2018-12-21 2023-04-19 Memorial Sloan Kettering Cancer Center Analogues de salicyl-adénosinemonosulfamate et leurs utilisations
CN109400545B (zh) * 2018-12-24 2022-03-25 济南大学 一种精氨酸甲基转移酶5抑制剂及其应用
CN109369507A (zh) * 2018-12-26 2019-02-22 重庆市碚圣医药科技股份有限公司 一种n-(2,2-二乙氧基乙基)邻苯二甲酰亚胺的提纯方法
BR112021015796A2 (pt) * 2019-02-13 2021-10-13 Prelude Therapeutics, Incorporated Inibidor seletivo de proteína arginina metiltransferase 5 (prmt5)
US20220160747A1 (en) * 2019-03-20 2022-05-26 Korea Research Institute Of Chemical Technology Pharmaceutical composition comprising novel azolopyrimidine heterocyclic compound as active ingredient
SG11202110272SA (en) * 2019-03-25 2021-10-28 California Inst Of Techn Prmt5 inhibitors and uses thereof
SG11202110742TA (en) 2019-04-02 2021-10-28 Aligos Therapeutics Inc Compounds targeting prmt5
US20220152072A1 (en) * 2019-04-05 2022-05-19 Prelude Therapeutics, Incorporated Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
US12440506B2 (en) 2019-04-05 2025-10-14 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
KR20220016194A (ko) * 2019-05-30 2022-02-08 앤젝스 파마수티컬, 인크. Prmt5 억제제로서의 헤테로시클릭 화합물
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
ES2967457T3 (es) * 2019-06-10 2024-04-30 Lupin Ltd Inhibidores de PRMT5
MX2021015363A (es) * 2019-06-12 2022-04-06 Janssen Pharmaceutica Nv Intermedios espirobicíclicos novedosos.
WO2021055797A1 (fr) * 2019-09-18 2021-03-25 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
AU2020372002A1 (en) * 2019-10-21 2022-05-26 Accent Therapeutics, Inc Mettl3 modulators
PE20221154A1 (es) * 2019-10-22 2022-07-18 Lupin Ltd Combinacion farmaceutica de inhibidores de prmt5
GB201915447D0 (en) * 2019-10-24 2019-12-11 Johnson Matthey Plc Polymorphs of avapritinib and methods of preparing the polymorphs
JP7664248B2 (ja) * 2019-12-03 2025-04-17 ルピン・リミテッド Ｐｒｍｔ５阻害剤としての置換ヌクレオシドアナログ
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
MX2022007652A (es) 2019-12-19 2022-09-23 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal.
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
CA3171648A1 (fr) 2020-02-18 2021-08-26 Gilead Sciences, Inc. Composes antiviraux
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
CN111233869B (zh) * 2020-03-12 2022-09-16 杭州新博思生物医药有限公司 用于制备瑞德西韦关键中间体的新化合物及其制备方法
US20220112194A1 (en) * 2020-04-01 2022-04-14 Aligos Therapeutics, Inc. Compounds targeting prmt5
US20240101589A1 (en) * 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
CN112645875A (zh) * 2020-12-09 2021-04-13 深圳海王医药科技研究院有限公司 一种盐酸丙卡特罗杂质的制备方法
CN117120444A (zh) 2021-04-16 2023-11-24 吉利德科学公司 使用酰胺制备卡巴核苷的方法
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物
CN117157297A (zh) * 2021-07-20 2023-12-01 上海齐鲁制药研究中心有限公司 Prmt5抑制剂
CN115703796A (zh) * 2021-08-09 2023-02-17 苏州恩泰新材料科技有限公司 一种瑞德西韦重要中间体制备方法
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
GB202117230D0 (en) 2021-11-29 2022-01-12 Argonaut Therapeutics Ltd Peptide vaccine
GB202203588D0 (en) 2022-03-15 2022-04-27 Argonaut Therapeutics Ltd Cancer diagnostic
CN116655638B (zh) * 2022-05-12 2024-01-26 上海齐鲁制药研究中心有限公司 氘代prmt5抑制剂
CN116003339B (zh) * 2022-12-01 2024-06-28 南京师范大学 一种巨噬细胞迁移抑制因子mif双光子荧光探针及其制备方法和应用
WO2024170488A1 (fr) 2023-02-13 2024-08-22 Astrazeneca Ab Inhibiteur de prmt5 destiné à être utilisé en thérapie anticancéreuse
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (fr) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 destiné à être utilisé dans le traitement d'une maladie ou d'un trouble lié à une protéine ras
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
EP4553080A1 (fr) 2023-11-07 2025-05-14 Ustav Organicke Chemie a Biochemie AV CR, v.v.i. Dérivés de nucléosides utilisés en tant qu'agents antiviraux contre les coronavirus
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
US7034147B2 (en) 2001-11-29 2006-04-25 Irm Llc Nucleoside analog libraries
MXPA04008008A (es) * 2002-02-19 2005-03-23 Cv Therapeutics Inc Agonistas parciales y completos de receptores de adenosina a1.
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
US7144674B2 (en) * 2002-03-20 2006-12-05 Sumitomo Chemical Company, Limited Positive resist composition
AU2002951247A0 (en) * 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
JPWO2005005450A1 (ja) 2003-07-15 2006-08-24 三井化学株式会社 環状ビスジヌクレオチドの合成方法
AU2004311702A1 (en) 2003-12-19 2005-07-21 Koronis Pharmaceuticals, Inc. Mutagenic heterocycles
WO2006078752A2 (fr) 2005-01-21 2006-07-27 Methylgene, Inc. Inhibiteurs d'adn-methyltransferase
US20110159111A1 (en) 2006-06-29 2011-06-30 Astex Therapeutics Limited Pharmaceutical combinations
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
AU2009298802A1 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
SG181703A1 (en) 2009-12-18 2012-07-30 Harvard College Beta-cell replication promoting compounds and methods of their use
CN103339139A (zh) * 2010-12-03 2013-10-02 Epizyme股份有限公司 组蛋白甲基转移酶的7-氮杂嘌呤调节剂及其使用方法
CA2819620A1 (fr) 2010-12-03 2012-06-21 Epizyme, Inc. Modulateurs d'histone methyltransferase et leurs procedes d'utilisation
CA2819894A1 (fr) 2010-12-16 2012-06-21 Abbvie Inc. Composes antiviraux
US9284343B2 (en) 2011-04-04 2016-03-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides
US20140357594A1 (en) 2011-10-24 2014-12-04 Glaxosmithkline Intellectual Property (No.2) Limited New compounds
WO2013151975A1 (fr) 2012-04-02 2013-10-10 Northeastern University Compositions et procédés d'inhibition de méthyltransférases
WO2014035140A2 (fr) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Composés et compositions pour la modulation de l'activité histone méthyltransférase
US20140100184A1 (en) 2012-08-31 2014-04-10 Baylor College Of Medicine Selective inhibitors of histone methyltransferase dot1l
HRP20182037T1 (hr) 2012-12-21 2019-02-08 Epizyme, Inc. Inhibitori prmt5 i njihova uporaba
WO2014100695A1 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
EP3406607A1 (fr) 2012-12-21 2018-11-28 Epizyme, Inc. Inhibiteurs prmt5 contenant de la dihydro- ou tétrahydroisoquinoline et leurs utilisations
WO2014100716A1 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
US9856218B2 (en) 2013-03-15 2018-01-02 Ohio State Innovation Foundation Inhibitors of PRMT5 and methods of their use
EP3091984B1 (fr) 2014-01-09 2020-04-22 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Benzoxazine substituée et composés associés
EP3160477A4 (fr) 2014-06-25 2018-07-04 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
EP3164130B1 (fr) 2014-07-01 2019-08-07 Millennium Pharmaceuticals, Inc. Composés hétéroaryle utiles en tant qu'inhibiteurs de l'enzyme d'activation sumo
WO2016135582A1 (fr) 2015-02-24 2016-09-01 Pfizer Inc. Dérivés de nucléosides substitués utiles en tant qu'agents anticancéreux
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
AU2017230658B2 (en) 2016-03-10 2021-03-04 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
MA46341A (fr) * 2016-10-03 2019-08-07 Janssen Pharmaceutica Nv Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
WO2018065365A1 (fr) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
AU2018225312B2 (en) 2017-02-27 2024-02-08 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
MA51004A (fr) 2017-12-08 2020-10-14 Janssen Pharmaceutica Nv Nouveaux analogues spirobicycliques

Also Published As

Publication number Publication date
BR112018003595A2 (pt) 2018-09-25
HK1253898A1 (zh) 2019-07-05
KR102716092B1 (ko) 2024-10-10
HRP20211997T1 (hr) 2022-04-01
MA42678A (fr) 2021-05-19
PH12021552054A1 (en) 2022-05-02
AU2016311295B2 (en) 2020-10-22
US11318157B2 (en) 2022-05-03
JP6917978B2 (ja) 2021-08-11
MX392554B (es) 2025-03-24
HK1257099A1 (en) 2019-10-11
NZ740528A (en) 2024-11-29
BR112018003595B1 (pt) 2024-03-12
JP2024012405A (ja) 2024-01-30
CY1125359T1 (el) 2024-02-16
MY198472A (en) 2023-08-31
US20230330127A1 (en) 2023-10-19
JP2018528946A (ja) 2018-10-04
PH12018500425A1 (en) 2018-09-10
TWI730980B (zh) 2021-06-21
CA2992688A1 (fr) 2017-03-02
EP3341368B1 (fr) 2021-10-06
TW202146414A (zh) 2021-12-16
MA42678B1 (fr) 2021-11-30
IL257664A (en) 2018-04-30
US11883367B2 (en) 2024-01-30
HUE057312T2 (hu) 2022-05-28
US20230071711A1 (en) 2023-03-09
AU2021200345A1 (en) 2021-03-18
NZ779003A (en) 2024-12-20
KR20180041222A (ko) 2018-04-23
TW202321249A (zh) 2023-06-01
SI3341368T1 (sl) 2022-01-31
BR122023020317A2 (pt) 2023-12-12
AU2021200345B2 (en) 2022-08-04
LT3341368T (lt) 2021-12-10
ES2901972T3 (es) 2022-03-24
DK3341368T3 (da) 2021-12-20
CN107922413B (zh) 2021-10-01
TWI791251B (zh) 2023-02-01
US10653711B2 (en) 2020-05-19
PE20180929A1 (es) 2018-06-08
AU2022215260B2 (en) 2024-04-18
CN107922413A (zh) 2018-04-17
SG10202003775VA (en) 2020-06-29
EP3341368A1 (fr) 2018-07-04
PT3341368T (pt) 2021-12-09
IL282537A (en) 2021-06-30
IL311843A (en) 2024-05-01
MD3341368T2 (ro) 2022-02-28
JP7720732B2 (ja) 2025-08-08
TW201718575A (zh) 2017-06-01
CL2018000510A1 (es) 2018-07-06
TWI870767B (zh) 2025-01-21
AU2024202052A1 (en) 2024-04-18
MX2018002326A (es) 2018-04-11
CN114057815A (zh) 2022-02-18
AU2016311295A1 (en) 2018-02-08
SMT202100725T1 (it) 2022-01-10
AU2022215260A1 (en) 2022-09-01
TN2018000043A1 (en) 2019-07-08
EP3974428A1 (fr) 2022-03-30
CN114057815B (zh) 2025-02-25
PE20221629A1 (es) 2022-10-19
RS62698B1 (sr) 2022-01-31
EP4219496A1 (fr) 2023-08-02
US20180243328A1 (en) 2018-08-30
IL257664B (en) 2021-05-31
US20200360416A1 (en) 2020-11-19
AR105820A1 (es) 2017-11-15
MX2022005182A (es) 2022-05-16
CO2018002063A2 (es) 2018-07-19
EA201890573A1 (ru) 2018-07-31
PH12018500425B1 (en) 2022-09-02
JP2021169520A (ja) 2021-10-28
WO2017032840A1 (fr) 2017-03-02

Similar Documents

Publication Publication Date Title
IL282537A (en) Novel 6–6 bicyclic aromatic ring-converted nucleoside analogs for use as PRMT5 inhibitors
IL261559A (en) Nucleoside analogues are converted for use as prmt5 inhibitors
IL288519A (en) inhibitors of ret
IL286428A (en) Disubstituted heterocyclyl derivatives as inhibitors of cyclin-dependent kinases
ZA201800480B (en) New bicyclic compounds as dual atx/ca inhibitors
ZA201801032B (en) Bicyclic compounds as atx inhibitors
ZA202003528B (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
IL255570A (en) Bicyclic compounds as atx inhibitors
IL255511B (en) New bicyclic compounds as dual atx/ca inhibitors
EP3212657A4 (fr) Procédés de préparation d'analogues de nucléosides substitués
IL249456A0 (en) Methods for preparing analogues of modified nucleotides
IL265718B (en) Novel modified carbonucleoside analogs with monocyclic and cyclic ring systems as prmt5 inhibitors
HUE053463T2 (hu) Pirrolopirimidin vegyületek, amelyek használhatók JAK inhibitorokként
IL255357A0 (en) bicyclic compounds
IL256226A (en) Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
HK40096188A (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
HK40067051A (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside for use as prmt5 inhibitors
ZA201806016B (en) Substituted nucleoside analogues for use as prmt5 inhibitors